Lumos Pharma — Q1 2021 Earnings Presentation
11 slides from Lumos Pharma's earnings presentation, May 5, 2021
Slide 1: First Quarter 2021
1 First Quarter 2021 May 5, 2021
Slide 2: Forward Looking Statements
2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. (the “Company”) that involve substantial risks and uncertainties. All such statements contained in this presentation are forward-looking statements within the meaning of The Private Securities Li
Slide 3: Agenda
3 Agenda • Lisa Miller, Senior Director of Investor Relations • Rick Hawkins, CEO, President & Chairman • John McKew, PhD, COO & CSO • Lori Lawley, SVP of Finance & Incoming CFO
Slide 4: First Quarter 2021 Update
4 First Quarter 2021 Update LUM-201 Data PGHD Trials Solid Cash Position • Final tranche of $26.0M from PRV monetization received in January 2021 • Cash runway through anticipated OraGrowtH210 & OraGrowtH212 trial readouts • Balance sheet flexibility to acquire additional rare disease assets • ENDO
Slide 5: PEMs Enrich Trials for Patients with Functional but Reduced GH Secretion
5 PEMs Enrich Trials for Patients with Functional but Reduced GH Secretion HP-GH – hypothalamic pituitary growth hormone 1 Bright 2021 JES 2 Blum 2021 JES Moderate (PEM+): Included in Clinical Trials Severe (PEM ): Excluded from Clinical Trials Predictive Enrichment Markers (PEMs): Data demonstrate
Slide 6: PK/PD Data Show LUM-201 Pulsatile MOA & Potential Efficacy in PGHD Patients
6 PK/PD Data Show LUM-201 Pulsatile MOA & Potential Efficacy in PGHD Patients PEM Positive PEM Negative Patient A Patient B Patient C Baseline 6months Baseline 6months Baseline 6months IGF-1 (ng/ml) 182 231 53 72 17 15 Q20m 24h GH Mean (ng/ml) 3.4 6.3 1.0 1.3 0.5 0.3 AUC (ng*hr/ml) 75.5 137.3 17.6 2
Slide 7: ENDO 2021 – LUM-201 Differentiated from Standard GH Secretagogues in PGHD
7 ENDO 2021 – LUM-201 Differentiated from Standard GH Secretagogues in PGHD Bright, G. ENDO 2021. Comparison of GH Responses to LUM-201 and to 2 standard GH stimulation tests *Note both parameters are displayed on logarithmic scales
Slide 8: OraGrowtH210 Trial: Phase 2b Trial Evaluating LUM-201 in PGHD
8 OraGrowtH210 Trial: Phase 2b Trial Evaluating LUM-201 in PGHD N=20 Daily rhGH injection N=20 LUM-201: 3.2 mg/kg/day N=20 LUM-201: 1.6 mg/kg/day N=20 LUM-201: 0.8 mg/kg/day • n = 80 • PEM(+) PGHD patients • Inclusion: stim GH ≥ 5ng/ml and baseline IGF-1 > 30ng/ml • rhGH treatment naïve • 40-50 tria
Slide 9: OraGrowtH212 Trial: Pharmacokinetic / Pharmacodynamic Trial in PGHD
9 • n = 24 • Open-label study • PGHD patients • rhGH-treatment naïve • 6-month dosing • Single, specialized clinical site • Q10 minute sampling for 12 hours OraGrowtH212 Trial: Pharmacokinetic / Pharmacodynamic Trial in PGHD Goals: • Confirm prior adult PK/PD data • Support future regulatory filings
Slide 10: Secure Cash Position
10 Secure Cash Position Metric Position Cash balance March 31, 2021 $114.1 million Non-dilutive resources included Final tranche of $26 million proceeds from PRV sale received in January 2021 Projected cash use per quarter through 2021 ~ $8 to $9 million Shares outstanding as of March 31, 2021 ~ 8.3
Slide 11: Therapeutics For Rare Diseases
11 Therapeutics For Rare Diseases